Collette Coll

Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.

Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue.

Argonaut Therapeutics Ltd. develops novel epigenetic therapies. It targets abnormal arginine methylation in cancer. The company was founded by Nicholas La Thangue and is headquartered in Oxford, the United Kingdom.